

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

AMLOT ET AL.

APPLICATION NO: NOT YET KNOWN

FILED: HEREWITH

FOR: USE OF CD25 BINDING MOLECULES IN THE TREATMENT OF
RHEUMATOID ARTHRITIS OR SKIN DISEASES

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the above-identified application as follows:

IN THE SPECIFICATION

Page 1, line 1, insert a case lineage paragraph as follows:

-- This application is a continuation of International Application No. PCT/EP99/05316
filed July 26, 1999. --

IN THE CLAIMS

Cancel claim 7.

Claim 8, line 1, replace "anyone of claims 4 to 6" with -- claim 4 --.

Claim 9, line 1, delete "or 2,".

Claim 10, line 1, delete "or 7,".

Add new claim 11:

(new) 11. A pharmaceutical composition comprising a CD25 binding molecule according to
claim 1 and an agent effective in treating rheumatoid arthritis or inflammatory or
hyperproliferative skin diseases.

TOP SECRET - USPTO EFS

REMARKS

A reference to the parent application, PCT/EP99/05316 filed July 26, 1999, has been inserted in the specification.

The claims have been amended to remove multiple dependencies.

Claim 7 has been cancelled and replaced by new claim 11.

Respectfully submitted,



Diane E. Furman
Attorney for Applicants
Reg. No. 31,104

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6924

Date: January 25, 2001